Int Urol Nephrol (2012) 44:761–767 17. Xie X-Y, Yang X, Zhang J-H, Liu Z-J (2007) Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real- time ﬂuorescence quantitative PCR. Ann Clin Biochem 44:523–528. doi:10.1258/000456307782268093 18. Badawy T, El-Abd S, Zahra M, Eid M, Abdou S et al (2008) Quantitative measurement of telomerase reverse transcrip- tase mRNA and chromosomal analysis of urine by M-FISH in the diagnosis and follow-up of bladder cancer. Mol Med Rep 1:325–333 19. Bowles L, Bialkowska-Hobrzanska H, Bukala B, Nott L, Razvi H (2004) A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol 11:2438–2444 20. Bu¨ttner P, Mosig S, Lechtermann A, Funke H, Mooren FC (2007) Exercise affects the gene expression proﬁles of human white blood cells. J Appl Physiol 102:26–36. doi: 10.1152/japplphysiol.00066.2006 21. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classiﬁcation. Cancer Res 64:4040–4048. doi:10.1158/0008-5472.CAN-03-3620 22. Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F et al (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13:4407–4414. doi:10.1158/1078-0432.CCR-07-0109 23. Barrett T, Edgar R (2006) Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Meth Enzymol 411:352–369. doi:10.1016/S0076-6879(06) 11019-8 24. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M et al (2010) Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS ONE 5:e13091. doi:10.1371/journal.pone.0013091 767 25. Cui W, Taub DD, Gardner K (2007) qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res 35:D805–D809. doi:10.1093/nar/gkl767 26. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A (2009) Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 22(Suppl 2):S70–S95. doi: 10.1038/modpathol.2009.1 27. van Rhijn BWG, van Leenders GJLH, Ooms BCM, Kirkels WJ, Zlotta AR et al (2010) The pathologist’s mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 57:1052–1057. doi:10.1016/ j.eururo.2009.09.022 28. Bollmann D, Bollmann M, Bankfalvi A, Heller H, Boll- mann R et al (2009) Quantitative molecular grading of bladder tumours: a tool for objective assessment of the biological potential of urothelial neoplasias. Oncol Rep 21:39–47 29. Sauter G, Haley J, Chew K, Kerschmann R, Moore D et al (1994) Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 57:508–514 30. De Luca A, Pignata S, Casamassimi A, D’Antonio A, Gridelli C et al (2000) Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. Clin Cancer Res 6:1439–1444 31. Kong X-T, Deng F-M, Hu P, Liang F-X, Zhou G et al (2004) Roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases. J Cell Biol 167:1195–1204. doi:10.1083/jcb.200406025 32. Wu X, Kakehi Y, Zeng Y, Taoka R, Tsunemori H, et al. (2005) Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: com- parison with cytokeratin 20. J Urol 174: 2138–2142, dis- cussion 2142–2143 123